Country	Trial name	Trial Acronym	Funder	Chief investigator	Trial objectives	Inclusion criteria
1	INNOVATE	INNOVATE	INNOVATE	INNOVATE	INNOVATE	INNOVATE
NL	Innovate trial	INNOVATE	Eurospine	Carmen Vleggeert-Lankamp	The INNOVATE Trial (INterNational study on Odontoid frActure Treatment in the Elderly) aims to identify the optimal treatment for odontoid fractures in the elderly patient.	≥ 55 years old Acute type II or III odontoid fracture according to Anderson and d'Alonzo classification (possibly in combination with other fractures) diagnosed using CT Less than two weeks after injury Informed consent
2	CASINO	CASINO	CASINO	CASINO	CASINO	CASINO
NL	Casino trial	CASINO	Dutch Health Authorities	Carmen Vleggeert-Lankamp	The CASINO Trial is a a prospective randomized multicenter study that compares Effectiveness of surgery versus prolonged conservative care in patients suffering from a herniated cervical disc.	Age 18-75 years Cervical radicular syndrome in one arm for at least 2 months Radiographic diagnosis of cervical disc herniation Informed consent
3	DOMINO	DOMINO	DOMINO	DOMINO	DOMINO	DOMINO
NL	Domino trial	DOMINO	Dutch Health Authorities	Wilco Jacobs	The DOMINO Trial is a randomised trial on the cost-effectiveness of two surgical treatment methods for neurogenic claudication or radicular leg pain in patients with spinal stenosis. The results of minimally invasive spinal fusion will be compared to the results of traditional open spinal fusion.	Neurogenic claudication or radicular leg pain Complaints are due to MRI confirmed existence of lytic or degenerative Spondylolisthesis of maximal 50% or Meyerding Grade II, or spinal stenosis, at one or two levels Spine is expected to destabilise after simple lumbar decompressive surgery Single or double level fusion indicated Insufficient response to conservative therapy (physical therapy, analgesic medications, or trans-foraminal corticosteroid injections) for at least 6 months Age is between and including 18-70 years Be able to understand the Dutch language and comprehend the questionnaires and patient information. Patients signed informed consent.

Country	Trial name	Trial Acronym	Funder	Chief investigator	Trial objectives	Inclusion criteria
4	Neck	Neck	Neck	Neck	Neck	Neck
NL	Neck trial	Neck	No	Carmen Vleggeert-Lankamp	The Netherlands Cervical Kinematics Trial (NECK) is a blinded randomised multicenter study that compares effectiveness of surgical treatment of cervical disc herniation.	Age 18-65 years Radicular signs and symptoms in one or both arms At least 8 weeks prior conservative treatment Radiographic diagnosis of cervical disc herniation and/or osteophyte at 1 level No previous cervical surgery Informed consent
5	Gill	Gill	Gill	Gill	Gill	Gill
NL	Sciatica-Gill trial	Gill	No	Pieter Schutte	The Sciatica-Gill Trial is a multicenter prospective randomised controlled trial, investigating the cost-effectiveness of nerve root decompression according to Gill versus instrumented fusion in the treatment of spondylolytic spondylolisthesis.	Age 18-70 years Low grade spondylolytic spondylolisthesis (grade I or II) Sciatica or neurogenic claudication with/without backpain Sympoms lasting more than 3 months Informed consent
6	RESTART	RESTART	RESTART	RESTART	RESTART	RESTART
UK	Restart or stop antithrombotics randomised trial	RESTART	BHF	Rustam Al-Shahi Salaman	For adults surviving spontaneous (non-traumatic) intracerebral haemorrhage (ICH) who had taken an antithrombotic (ie anticoagulant or antiplatelet)drug for the prevention of vaso-occlusive disease before the ICH, does a policy of starting antiplatelet drugs result on a beneficial net reduction of all serious vascular events over at least two years compared with a policy of avoiding antiplatelet drugs?	Patient aged ≥18years Spontaneous primary or secondary ICH Pt had taken antithrombotic drug(s) for the prevention of vaso-occlusive disease before ICH onset Randomisation more than 24hrs after ICH onset Pt and their doctor are uncertain about whether to start or avoid antiplatelet drugs pt is registered with a GP brain imaging that first diagnosed the ICH is available paricipant or representative consent

Country	Trial name	Trial Acronym	Funder	Chief investigator	Trial objectives	Inclusion criteria
7	ULTRA	ULTRA	ULTRA	ULTRA	ULTRA	ULTRA
NL	Ultra-early tranexamic acid afi	ULTRA	FONDS NUTS-OHRA	D Verbaan	To investigate whether treatment with ultra-early and short-term transexamic acid leads to a significantly higher percentage of patients with a favourable outcome	SAH within 24 hours after last haemorrhage Patient aged ≥18years
8	SCIBMO	SCIBMO	SCIBMO	SCIBMO	SCIBMO	SCIBMO
Belgium	Identification and characterization of novel antibody biomarkers in post-spinal cord injury	SCIBMO	Research Foundation Flande	Prof.Dr.Veerle Somers	Determine the antibody reactivity profile after spinal cord injury (SCI); Establish the true prevalence, specificity and pathogenic relevance of SCI-induced antibodies in humans; Identify antibody biomarkers that have diagnostic and prognostic and/or theranostic potential in SCI; Identify the SCI-induced autoantibody targets; Discover pathogenic antibodies that can be targeted in SCI-therapy	All traumatic and pathological spinal cord injury patients > 18 years both male and female
9	CENTER-TBI	CENTER-TBI	CENTER-TBI	CENTER-TBI	CENTER-TBI	CENTER-TBI
Belgium /UK	Collaborative Eurpoean Neurc	CENTER-TBI	European Commission FP7 program	Prof Andrew Maas	Prospective longitudinal non-randomised observational study acroos the severity spectrum of TBI in up to 80 sites from 22 countries over 18 months. The study will consist of 2 parts: CENTER-TBI core data study (n=5400) and CENTER-TBI registry (n=15,000-25,000). The project aims to advance the care for patients with traumatic brain injury, a field in medicine with one of the greatest unmet needs. Research aims are 1) better characterise TBI as a disease and describe in a European context and 2) identify the most effective clinical interventions for managing TBI	Observational study: clinical diagnosis of TBI and clinical indication for CT scan Core Data: Presentation within 24 hrs of injury and informed consent
10	Pilot study - Altzheimers	Pilot study - Altzheimers	Pilot study - Altzheimers	Pilot study - Altzheimers	Pilot study - Altzheimers	Pilot study - Altzheimers
Spain	Pilot study to evaluate the efficacy and safety of deep brain stimulation in Altzheimers disease		FEDER	Prof JA Barcia	Replicating the results of groups Lozano and Sturm, with Deep Brain Stimulation (DBS) for Alzheimer's disease (AD), ensuring that DBS for AD slows progression of the disease: Bilateral stimulation of the pillar of the fornix to 130 Hz mainly produces an improvement in memory functions in early AD, while bilateral stimulation of Meynert nucleus basalis to 20 Hz produces an improvement in cognitive functions primarily in early Alzheimer's disease.	Age: between 60 and 80 years Diagnostic criteria for possible AD (McKhann G et al 1983) Diagnosis of AD in the past 2 years Presence of tau, Abeta fosfotau or in CSF. Clinical dementia scores (1.0 or 0.5 CDR Morris JC. Et al 1992) Score between 18 and 24 on the Mini-Mental Score Examination (MMSE)) (Folstein et al 1975 MF)

Country	Trial name	Trial Acronym	Funder	Chief investigator	Trial objectives	Inclusion criteria
						Inadequate clinical response to cholinergic medication or side effects of it, receiving a stable dose of cholinesterase inhibitors in the past 6 months. Informed consent of the patients or family members of the patient Approval by an independent ethics committee.
11	BIOHYBRIDS	BIOHYBRIDS	BIOHYBRIDS	BIOHYBRIDS	BIOHYBRIDS	BIOHYBRIDS
Spain	Phase I clinical trial to determine the feasibility and safety of using biohybrid biomaterials with allogeneic stem cells are expanded from fat for the local treatment of stroke by stroke	BIOHYBRIDS	FEDER	Prof. Juan José Lopez-Ibor	Evaluating the safety of using adult mesenchymal stem cells derived from adipose tissue into 2 million doses by the BIOMATERIAL (hyaluronic acid in the form of cylinders 20 dimensions of 8 mm in length and 0.8 mm diameter) in the ischemic stroke	Ability of the patient or legal representative, to understand and sign informed consent for study participation Age 40-65 years at the time of inclusion. Woman or man with the diagnosis of cerebral ischemic stroke at least six months before inclusion. MRI or CT scan showing lesions compatible with cerebral ischemic stroke. Patients with intermediate sequelae measured by modified Rankin Scale of 2-4

Country	Trial name	Trial Acronym	Funder	Chief investigator	Trial objectives	Inclusion criteria
12	Pilot study-schizophrenia	Pilot study-schizophrenia	Pilot study-schizophrenia	Pilot study-schizophrenia	Pilot study-schizophrenia	Pilot study-schizophrenia
Spain	Pilot clinical trial to evaluate the safety and efficacy of deep brain stimulation in patients with drug-resistant schizophrenia.		Feder	FEDER	The primary objective is to evaluate the safety of Deep Brain Stimulation (DBS) the ventral tegmental area in patients with treatment-resistant schizophrenia.	Age: 18 to 50 years. Diagnosis of schizophrenia according to DSM IVTR. Time course of the disease for at least two years and three active symptoms (positive, negative and cognitive) fields maintained for at least six months prior to enrollment in the study. Schizophrenia resistant 4. Criteria by the following parameters:

Country	Trial name	Trial Acronym	Funder	Chief investigator	Trial objectives	Inclusion criteria
						Insufficient response to 3therapeutic trials with antipsychotic monotherapy or in combination with full doses according to clinical practice guidelines currently validated, including clozapine treatment in all cases (unless contraindicated) to the max tolerated dose (max 900 mg / day) for periods of a min of 6 weeks each, with a guarantee of full adherence to all of them. In addition to drug treatment they have received a bid ETT treatment for at least 9 sessions effective regimen 2/3 sessions per week in the absence of contraindications for the technique. In this case it must elapse at least 1 month after the last session before inclusion in the study. It is considered insufficient response to this study, the presence of positive, negative and / or cognitive symptoms with an intensity of moderate / severe and extreme that produce a significant impact on the patient's life in terms of disability at the time of study entry . equal to or greater than 6 in the CGI score and 40 exceeding the GAF scale score. Accept the study participation by informed consent in the presence of a first degree if any or possibly nearest. For patients legally incapacitated IQ must be signed by their legal guardian. favors the inclusion of each patient by an external ethics committee evaluation.
13	CELICTUS	CELICTUS	CELICTUS	CELICTUS	CELICTUS	CELICTUS
Spain	Phase IIa clinical trial to determine the feasibility /safety of allogeneic stem cells expanded from fat in the local tx of stroke in the territory of the MCA	CELICTUS	FEDER	Prof. Juan Antonio Barcia	Safety assessment of the administration of adult mesenchymal stem cells derived from adipose tissue in a dose of 10 million in the acute phase of stroke.	Ability to understand and sign informed consent to study participation consent Age 25-70 years at the time of inclusion. Woman or man with the diagnosis of stroke per full stroke of the middle cerebral artery, at least six months before inclusion. MRI or CT scan showing lesions compatible with a complete infarction of the middle cerebral. Patients with severe sequelae measured by Rankin 2 or less.

Country	Trial name	Trial Acronym	Funder	Chief investigator	Trial objectives	Inclusion criteria
14	Cerebellar Mutism Syndrome	Cerebellar Mutism Syndrome	Cerebellar Mutism Syndrome	Cerebellar Mutism Syndrome	Cerebellar Mutism Syndrome	Cerebellar Mutism Syndrome
Denmark	Nordic study of the Cerebellar Mutism Syndrome in children after tumor surgery		Rigshospitalet Denmark, Thwe Danish and Swedish Children's Cancer Foundations	Dr. Med Marianne Juhler	The purpose of this study is to determine why up to 25% of the pediatric patients who have surgery for a tumor in the posterior fossa develop the Cerebellar Mutism Syndrome (CMS). Furthermore the purpose is to explore the clinical course and the best treatment of the syndrome as well as the role of genetics. It is a prospective multicenter study which started in October/November 2014 in 20 different	Age < 18 years at the date of first imaging showing this tumour Tumour in the cerebellum/4th ventricle/brainstem with intention to treat with surgical resection or open biopsy. Second and further surgeries are also included

Country	Trial name	Trial Acronym	Funder	Chief investigator	Trial objectives	Inclusion criteria
					centers in 5 Nordic/Baltic countries	Informed consent from custodial parent(s)
15	Spina Bifida	Spina Bifida	Spina Bifida	Spina Bifida	Spina Bifida	Spina Bifida
Denmark	Incidence and pregnancy outcome of prenatally diagnosed spina bifida in Denmark in 2008-2015		Institute of Clinical Medicine, University of Aarhus, Middle Region of Denmark	Charlotte Rosenkrantz Bodin	Assess the incidence of pregnancies with a prenatal diagnosis of spina bifida in Denmark from 2008 and on, as well as the pregnancy outcome in these cases (including termination of pregnancy). In cooperation with international partners compare data from Denmark and Sweden (partner in Sweden: Eleonor Tiblad, MD, Ph.D, Center for Fetal Medicine, Karolinska University Hospital) and if possible also Saudi Arabia (partner in the Saudi Arabia collaboration: Marianne Juhler, MD, DMSc, Professor, Rigshospitalet, Denmark and Daniele Rigamonti, MD, professor, Chief of Staff, Department of Neurosurgery, John Hopkins University Hospital Aramco Health Care, Baltimore, USA)	Pregnant women in Denmark participating in prenatal examination program in the years 2008-2015
16	RESCUE-ASDH	RESCUE-ASDH	RESCUE-ASDH	RESCUE-ASDH	RESCUE-ASDH	RESCUE-ASDH
UK	Randomised Evaluation of Surgery with Craniectomy for patients Undergoing Evacuation of Acute Subdural Haematoma	RESCUE-ASDH	NIHR	Prof PJ Hutchinson	To compare the clinical and cost-effectiveness of decompressive craniectomy versus craniotomy for the management of adult head-injured patients undergoing evacuation of an acute subdural haematoma	Adult head-injured patients (aged >16 years) Acute subdural haematoma on CT The admitting neurosurgeon feels that the haematoma needs to be evacuated either by a craniotomy or decompressive craniectomy (bone flap >11 cm)
17	EARLYDRAIN	EARLYDRAIN	EARLYDRAIN	EARLYDRAIN	EARLYDRAIN	EARLYDRAIN
Germany	EARLYdrain- outcome after early lumbar CSF drainage in aneurysmal SAH	EARLYDRAIN		Dr.Stefan Wolf	To investigate whether drainage of cerebral spinal fluid via a lumbar route will improve outcome after Intracranial aneurysmal SAH	Age of 18 years or older Pre-morbid modified Rankin Scale (0 or 1) Aneurysm treatment performed in the first 48 hours after the initial hemorrhage. Informed consent

Country	Trial name	Trial Acronym	Funder	Chief investigator	Trial objectives	Inclusion criteria
18	DYNORFUSE	DYNORFUSE	DYNORFUSE	DYNORFUSE	DYNORFUSE	DYNORFUSE
Germany	Posterior dynamic stabilization versus fusion in the treatment of lumbar degenerative disease	DYNORFUSE		Dr. Bernhard Meyer	To compare posterior dynamic stabilization with fusion in the treatment of lumbar degenerative disease	Age >18 years Mono- or bisegmental symptomatic lumbar degenerative disease with or without stenosis Indication for fusion with (i) spondylolisthesis of at least 5mm or segmental vertebral motion of at least 3mm or 10º on flexion/extension radiographs, (ii) predominant low back pain in combination with Modic changes Failure of adequate conservative measures for more than 3 months Correctly signed informed consent form
19	Giant Aneurysma	Giant Aneurysma	Giant Aneurysma	Giant Aneurysma	Giant Aneurysma	Giant Aneurysma
Germany	Giant Intracranial Aneurysm Registry			Dr Julius Dengler	Generate detailed insight into which therapies of giant intracranial aneurysms are being conducted, to document the natural history and the outcome of treatment over 5 years after inclusion into the Registry and to follow imaging data of giant aneurysms over years after diagnosis.	Diagnosis of giant intracranial aneurysm
20	DELTA SYSTEM	DELTA SYSTEM	DELTA SYSTEM	DELTA SYSTEM	DELTA SYSTEM	DELTA SYSTEM
Germany	Safety and Performance of the Delta System in the Treatment of Vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH) Patients			Prof. Peter Vajkoczy	to evaluate the safety and performance of the Delta system in the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) patients	Male and female (18 -75) aSAH patients with secured aneurysm. Patient has cerebral vasospasm and is anesthetized and intubated. Cerebral vasospasm is manifested by: Mean Flow Velocity >120 cm/sec in the intracranial ICA, MCA or ACA or MFV >110 cm/sec in the PCA, or >85 cm/sec in the vertebral or basilar arteries, as measured by TCD Or: Extra/intracranial ratio for the carotid watershed (MCA, ACA, intracranial ICA)>3, or a proximal/distal ratio for the vertebrobasilar (VB) system > 2. Or: Affected/contralateral MCA MFV ratio ≥1.5.

Country	Trial name	Trial Acronym	Funder	Chief investigator	Trial objectives	Inclusion criteria
						Or Affected / baseline MCA MFV ratio ≥1.5. AND: Vasoconstriction of at least 33% in at least one of the main cerebral arteries, measured by DSA or CTA Hemodynamically stable, including subjects who are treated for fever, hydrocephalus, rebleeding, infection or metabolic abnormalities and are stable. For pre-menopausal females - a negative pregnancy test, using an accepted method of birth control and avoid breast feeding for the duration of the trial A legally Authorized representative has signed informed consent.
21	SWITCH	SWITCH	SWITCH	SWITCH	SWITCH	SWITCH
Switzerland	Decompressive Hemicraniectomy in Intracerebral Hemorrhage	SWITCH		Dr Urs Fischer Prof. Jurgen Beck	To determine whether decompressive surgery and best medical treatment in patients with spontaneous ICH will improve outcome compared to best medical treatment only	Written informed consent of the patient or of patient's next of kin plus consent of an independent physician if patient is unable to consent before randomization Acute stroke syndrome due to a spontaneous ICH, defined as the sudden occurrence of bleeding into the parenchyma of the basal ganglia and/or thalamus that may extend into the ventricles and into the cerebral lobes, and into the subarachnoid space, confirmed by clinical history and imaging Age: ≥18 to ≤75 years Glasgow coma scale (GCS) <14 and >7 Neurological deficit with a NIHSS score of ≥10 and ≤30

Country	Trial name	Trial Acronym	Funder	Chief investigator	Trial objectives	Inclusion criteria
						Able to be randomly assigned to surgical treatment within 66 hours after ictus Surgery performed not later than 6 hours after randomization Volume of hematoma ≥30 ml and ≤100 ml Stable clot volume International normalized ratio (INR) <1.5, thrombocytes >100 T/ml
22	Fibrinolysis in aSAH	Fibrinolysis in aSAH	Fibrinolysis in aSAH	Fibrinolysis in aSAH	Fibrinolysis in aSAH	Fibrinolysis in aSAH
France	Intraventricular fibrinolysis vs EVD in aSAH: a randomised controlled trial		French Ministry of Health	Dr Thomas Gaberel	To evaluate the impact of intraventricular fibrinolysis after aneurysmal subarachnoid haemorrhage in terms of neurological functional outcome at 6 months	age 18-75 SAH associated hydrocephalus requiring EVD confirmation of intracranial aneurysm by vascular imaging onset to admission under 24 hrs exclusion of aneurysm by surgical clipping or coiling before IVF

Exclusion criteria	Sample size	Recruitment to date	Further sites required	Require sites in UK	Trial website and main contact(s)
INNOVATE	INNOVATE	INNOVATE	INNOVATE	INNOVATE	INNOVATE
Rheumatoid arthritis Ankylosing spondilytis Previous treatment for odontoid fracture Communication with patient is hampered (e.g. language barrier, severe cognitive impairment, coma)	275	52	Yes	Yes	www.lumc.nl/org/sips/onderzoeken/lopende-onderzoeken/innovate/
CASINO	CASINO	CASINO	CASINO	CASINO	CASINO
Signs of myelopathy Severe paresis (MCR ≤3) Instability of the cervical spinal column requiring stabilisation Pregnancy Severe life-threatening of psychiatric illness Insufficient knowledge of Dutch language Planned emigration in the year after randomization Cervical spine surgery in the past	400	6	Yes	No	www.lumc.nl/org/sips/onderzoeken/lopende-onderzoeken/1203300301323237/ Carmen Vleggeert-Lankamp
DOMINO	DOMINO	DOMINO	DOMINO	DOMINO	DOMINO
A potential subject who meets any of the following criteria will be excluded from participation in this study: Iatrogenic Spondylolisthesis or a slip of more than 50% or more than Meyerding Grade II. Inflammatory arthritis, Osteoporosis or other metabolic bone disease to a degree that it would influence fusion. Contraindication for surgery.	340	0	Yes	No	www.lumc.nl/org/sips/onderzoeken/lopende-onderzoeken/Domino/?setlanguage=English&setcountry=en Jeroen Huybregts

Exclusion criteria	Sample size	Recruitment to date	Further sites required	Require sites in UK	Trial website and main contact(s)
Neck	Neck	Neck	Neck	Neck	Neck
Increased motion on dynamic studies (> 3 mm) Involved disc level fused or very narrow Severe kyphosis of the involved disc level Neck pain only Infection Metabolic and bone diseases Neoplasma or trauma Spinal anomaly (Klippel Feil, Bechterew, OPLL) Severe mental or psychiatric disorder Inadequate Dutch language	182	104	No	No	www.lumc.nl/org/sips/onderzoeken/lopende-onderzoeken/1004201050243237/ Lisette Boscher
Gill	Gill	Gill	Gill	Gill	Gill
Highgrade spondylolytic spondylolisthesis (grade III or IV) Back pain only Abnormal mobility on dynamic X-ray (> 3 mm) Progressive spondylolisthesis Previous lumbar surgery at level of spondylolisthesis Severe comorbidity / contraindication surgery Planned emigration in the year after surgery Inadequate knowlegde of Dutch language Pregnancy	220	84	No	No	www.lumc.nl/org/sips/onderzoeken/lopende-onderzoeken/81126023310221/ Pieter Schutte
RESTART	RESTART	RESTART	RESTART	RESTART	RESTART
ICH due to preceding trauma or haemorrhagic transformation of ischaemic stroke Pt is taking anticoagulant drug pt is pregnant, breastr feeding or of child bearing age and not taking contraception pt is being treated or folowed up in a CTIMP other than TICH2 Pt and carer unable to understand English	720	92	Yes	Yes	www.restarttrial.org Rustam Al-Shahi-Salman

Exclusion criteria	Sample size	Recruitment to date	Further sites required	Require sites in UK	Trial website and main contact(s)
ULTRA	ULTRA	ULTRA	ULTRA	ULTRA	ULTRA
no LOC WFNS 1-2 with a perimesencephalic haemorrhage pattern traumatic SAH venous thrombosis	950	121	Yes	?	www.ultrastudie.nl D Verbaan
SCIBMO	SCIBMO	SCIBMO	SCIBMO	SCIBMO	SCIBMO
Pre-existing autoimmune disorders	100	35	Yes	Yes	www.trialregister.nl/trialreg/admin/rctview.asp?TC=4268 Prof Dr V Somers
CENTER-TBI	CENTER-TBI	CENTER-TBI	CENTER-TBI	CENTER-TBI	CENTER-TBI
Core data: severe pre-existing neurological disorder that would confound assessments	5400				www.center-tbi.eu Antwerp University Hospital, Dept of Neurosurgery
Pilot study - Altzheimers	Pilot study - Altzheimers	Pilot study - Altzheimers	Pilot study - Altzheimers	Pilot study - Altzheimers	Pilot study - Altzheimers
Structural brain disorders, such as tumor, stroke or intracranial hematoma Other neurological or psychiatric diagnoses Medical comorbidities that may exclude patients from surgery	12	1	YES		Prof. Juan Antonio Barcia

Exclusion criteria	Sample size	Recruitment to date	Further sites required	Require sites in UK	Trial website and main contact(s)
BIOHYBRIDS	BIOHYBRIDS	BIOHYBRIDS	BIOHYBRIDS	BIOHYBRIDS	BIOHYBRIDS
Patient tracheotomy or noninvasive ventilation for more than 16 hours a day. Presence of multiple non-lacunar infarcts on cranial CT or former independent resonance that cause the clinical picture. History of intracranial hemorrhage or subarachnoid hemorrhage. Patients who have used antipsychotics at therapeutic doses, even to sleep in the month prior to inclusion. History of cancer in the three years prior to inclusion. Previous ideas of suicide. Patients with a known history of alcohol or drug abuse Patients with a history of cardiac, renal, hepatic, systemic, immune, and which the researcher may influence patient survival during the test control disease. Patients with other chronic neurological injuries such as Parkinson's disease, tremor, neurodegenerative disease, ALS, etc. History of uncontrolled hypertension. Pregnant or lactating Women of childbearing potential (not undergone hysterectomy without bilateral or postmenopausal ovary removal for 12 months) that would not have agreed to use a medically approved method of contraception while receiving study medication until trial completion Patients with planned surgery for any cause. Participating in another clinical trial. Patients with immunotherapy.	6	1	Yes		Prof. Juan Antonio Barcia

Exclusion criteria	Sample size	Recruitment to date	Further sites required	Require sites in UK	Trial website and main contact(s)
Patients residing in institutionalized regime in center of brain damage. Patient with difficult or impossible location. Inability to cooperate with the rehabilitation treatment Any other reason which in the opinion of the researcher may influence the patient or clinical trial for their involvement in the same. Existence of a marked brain atrophy on brain MRI. Patients with active acute or chronic infectious disease including patients with hepatitis B, hepatitis C and HIV. Anticoagulated patients Allergy or intolerance to prior hyaluronic acid in any of its forms and modes of administration.					
Pilot study-schizophrenia	Pilot study-schizophrenia	Pilot study-schizophrenia	Pilot study-schizophrenia	Pilot study-schizophrenia	Pilot study-schizophrenia
Any change in the physical and neurological examination, intracranial lesions (tumors or vascular malformations) in neuroimaging, or history of head trauma. Abuse of or reliance on toxic (except nicotine or caffeine) at the time of selection. concomitant infectious or neoplastic diseases and that may exclude patients from surgery or those with poor control at the time of assessment (diabetes mellitus, hypertension, COPD) contraindication for surgery.	6	1	Yes		Prof. Juan Antonio Barcia

Exclusion criteria	Sample size	Recruitment to date	Further sites required	Require sites in UK	Trial website and main contact(s)
CELICTUS	CELICTUS	CELICTUS	CELICTUS	CELICTUS	CELICTUS
Patient tracheotomy or noninvasive ventilation for more than 16 hours a day. Presence of multiple non-lacunar infarcts on cranial CT or former independent resonance that cause the clinical picture. History of intracranial hemorrhage or subarachnoid hemorrhage. Previous Thoughts of suicide Patients with a known history of alcohol or drug abuse	20	1	Yes		Prof. Juan Antonio Barcia

Exclusion criteria	Sample size	Recruitment to date	Further sites required	Require sites in UK	Trial website and main contact(s)	
Patients with a history of cardiac, renal, hepatic, systemic, immune, and which the researcher may influence patient survival during the test control disease. Patients with other chronic neurological injuries such as Parkinson's disease, tremor, neurodegenerative disease, ALS, etc .. History of uncontrolled hypertension. Pregnant or breast-feeding Women of childbearing potential (not undergone hysterectomy without bilateral or postmenopausal ovary removal for 12 months) that would not have agreed to use a medically approved method of contraception while receiving study medication until trial completion Patients with planned surgery for any cause. Participating in another clinical trial. Patients with immunotherapy. Patients residing in institutionalized regime in center of brain damage Patient with difficult or impossible location. Inability to cooperate with the rehabilitation treatment Any other reason which in the opinion of the researcher may influence the patient or clinical trial for their involvement in the same. Existence of a marked brain atrophy on brain MRI Patients with active acute or chronic infectious disease including patients with hepatitis B, hepatitis C and HIV.						
Cerebellar Mutism Syndrome	Cerebellar Mutism Syndrome	Cerebellar Mutism Syndrome	Cerebellar Mutism Syndrome	Cerebellar Mutism Syndrome	Cerebellar Mutism Syndrome	
None	500	6	Yes	Yes	Morten Wibroe	Marianne Juhler

Exclusion criteria	Sample size	Recruitment to date	Further sites required	Require sites in UK	Trial website and main contact(s)
Spina Bifida	Spina Bifida	Spina Bifida	Spina Bifida	Spina Bifida	Spina Bifida
	350,000	150,000	yes	yes	Charlotte Rosenkrantz Bodin Blegdammen 2, 2nd floor, 8000 Aarhus C e-mail: chbodi@rm.dk
RESCUE-ASDH	RESCUE-ASDH	RESCUE-ASDH	RESCUE-ASDH	RESCUE-ASDH	RESCUE-ASDH
Bilateral unresponsive dilated pupils of ≥5mm and/or brainstem injuries on CT Uncorrected coagulopathy Bilateral acute subdural haematomas both requiring evacuation Previous enrolment in RESCUE-ASDH study Severe pre-existing physical or mental disability or severe co-morbidity which would lead to a poor outcome even if the patient made a full recovery from the head injury	990	5	Yes	Yes	www.rescueasdh.org Alicia Gore
EARLYDRAIN	EARLYDRAIN	EARLYDRAIN	EARLYDRAIN	EARLYDRAIN	EARLYDRAIN
Subarachnoid hemorrhage of other than aneurysmal origin Pregnancy Concurrent participation in another interventional trial (participation in an observational trial is allowed) Life expectancy less than 1 year for other reasons than the actual SAH Other concomitant severe disease that would confound with treatment Other clear contraindication for treatment	300				Stefan Wolf stefan.wolf@charite.de

Exclusion criteria	Sample size	Recruitment to date	Further sites required	Require sites in UK	Trial website and main contact(s)
DYNORFUSE	DYNORFUSE	DYNORFUSE	DYNORFUSE	DYNORFUSE	DYNORFUSE
Olisthesis more than grade I, spondylolisthesis vera, spondylolysis without olisthesis or spinal deformity (i.e. scoliosis of more than 20°, sagittal imbalance) Significant comorbidity impeding with surgical success (e.g. osteoporosis, rheumatoid arthritis, mental illness) Previous fusion or stabilization surgery	300				Caspar Sennefelder caspar.sennefelder@mri.tum.de
Giant Aneurysma	Giant Aneurysma	Giant Aneurysma	Giant Aneurysma	Giant Aneurysma	Giant Aneurysma
age younger than 18	105				Julius Dengler julius.dengler@charite.de
DELTA SYSTEM	DELTA SYSTEM	DELTA SYSTEM	DELTA SYSTEM	DELTA SYSTEM	DELTA SYSTEM
WFNS score 5 Unsecured aneurysm or Intracranial/SAH of other than aneurysmal origin. Signs attributable to serious aneurismal surgical procedure-related complications. Patient underwent decompressive craniectomy. S/p Carotid Endarterectomy, or other neck intervention. Known carotid body tumor, past or present. Hemodynamic instability due to cardiac arrhythmia or due to any other cause.	23				Ronnie Levy ronniel@samsonneuro.com

Exclusion criteria	Sample size	Recruitment to date	Further sites required	Require sites in UK	Trial website and main contact(s)
Had a myocardial infarction, unstable angina or syncope, congestive heart failure that require hospitalization or ejection fraction ≤ 40% within the past 3 months. Note: Elevated Troponin is expected after aSAH and will not exclude patients. Had a stroke, within the past 1 year or transient ischemic attack at the last 3 months. Any anatomical variation or thrombotic finding that according to the physician judgment is not eligible. Renal insufficiency (Creatinine X2 of the normal). Allergic to contrast media with no response to steroid pretreatment. Are unable or unwilling to fulfill the protocol follow-up requirements Are enrolled in another concurrent clinical trial, without prior approval of Samson NS and the PI. Have an uncontrolled comorbid medical condition that would adversely affect their health if they are enrolled.					
SWITCH	SWITCH	SWITCH	SWITCH	SWITCH	SWITCH
ICH due to known or suspected structural abnormality in the brain (e.g., intracranial aneurysm, brain arteriovenous malformation, brain tumor) or brain trauma, or previous stroke thrombolysis Cerebellar or brainstem hemorrhage Exclusive lobar hemorrhage Known advanced dementia or significant pre-stroke disability Concomitant medical illness that would interfere with outcome assessment and follow-up	300				www.switch-trial.ch Stefanie Lerch Grossen stephanie.lerch@insel.ch

Exclusion criteria	Sample size	Recruitment to date	Further sites required	Require sites in UK	Trial website and main contact(s)
Randomization not possible within 66 hours after ictus Pregnancy Prior major brain surgery within <6 month or prior DC Foreseeable difficulties in follow-up due to geographic reasons Known definite contraindication for a surgical procedure A very high likelihood that the patient will die within the next 24 hours on the basis of clinical and/or radiological criteria Previous participation in this trial or in another ongoing investigational trial Prior symptomatic ICH ICH secondary to thrombolysis Bilateral areactive pupils					
Fibrinolysis in aSAH	Fibrinolysis in aSAH	Fibrinolysis in aSAH	Fibrinolysis in aSAH	Fibrinolysis in aSAH	Fibrinolysis in aSAH
WFNS 5 on admission associated haematoma of more than 2cm in larger width SAH diagnosed on lumbar puncture, Fisher Grade 1 Impossibility to exclude aneurysm within 72 hr following rupture Previous treatment with antiplatelet therapy or treated with antiplatelet therapy after aneurysm exclusion severe coagulopathy, including oral vitamin K antagonist and new oral anticoagulant Pregnancy or lactating woman	440		yes	yes	Dr Thomas Gaberel thomas.gaberel@hotmail.fr